Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country

Figures & data

Table 1 Chemotherapy Regimens

Adjuvant*	AC every 3 weeks × 4 cycles
	AC every 3 weeks for 4 cycles followed by weekly paclitaxel × 12 weeks
	FEC every 3 weeks × 3 cycles followed by docetaxel every 3 weeks × 3 cycles
Paclitaxel ×12 weeks followed by FEC every 3 weeks × 3 cycles
Neoadjuvant^	AC every 3 weeks × 4 cycles followed by docetaxel every 3 weeks × 4 cycles (NSABP-B27)
Chemotherapy for metastatic disease^#	AC every 3 weeks (maximum 6 cycles)
	Docetaxel every 3 weeks till best response
	Paclitaxel weekly
	Capecitabine
	Capecitabine + docetaxel
	Gemcitabine
	Vinorelbine
	Cisplatin + gemcitabine
	Carboplatin + paclitaxel
Erbulin

Notes: *If HER2/Neu-positive, trastuzumab with taxanes added. ^{^}If HER2/neu-positive, trastuzumab and pertuzumab added. ^#If HER2/Neu-positive, trastuzumab and/or pertuzumab added based on protocol.

Abbreviations: AC, adriamycin–cyclophosphamide; FEC, 5-flurouracil–epirubicin–cyclophosphamide.

Table 2 Patient Characteristics (n=417)

		Number	Percentage
Age, years	21–25	14	3.4%
	26–30	59	14.1%
	31–35	137	32.8%
36–40	207	49.6%
Family history (first-degree)	Breast cancer	72	17.3%
Other cancers	20	4.8%
Histology	IDC	386	92.6%
	ILC	20	4.8%
Others	11	2.6%
Tumor size*	T1	92	26%
	T2	161	45.5%
	T3	79	22.3%
	T4	21	5.9%
Tx	1	0.28%
Lymph node*	Negative	117	33.1%
Positive	237	66.9%
Stage	I	47	11.3%
	II	158	37.9%
	III	149	35.7%
IV	63	15.1%
Grade*	I	9	2.5%
	II	163	46%
	III	182	51.4%
Unknown	1
Lymphovascular invasion*	Positive	172	48.6%
	Negative	180	50.8%
Unknown	2	0.56%
Hormone receptors	ER-positive–PR-positive	284	68.1%
	ER-positive–/PR-negative	32	7.7%
	PR-positive–ER-negative	20	4.8%
ER-negative–PR-negative	80	19.2%
HER2^#	Positive	122	31.5%
	Negative	265	68.5%
NA	30	7.8%
Triple-negative^#		37	9.6%

Notes: *From the 354 patients with nonmetastatic disease; ^#from the 387 with known HER2 status.

Figure 1 Overall survival (n=417). (A) Whole group (M0 and M1); (B) node-positive versus node-negative (M0 patients); (C) grade I/II versus grade-III (M0 patients); (D) age >30 versus ≤30 years (M0 patients).

Table 3 Cox Regression, Overall Survival

		P-value	HR	95% CI
Nodal metastasis	Positive	0.0043	3.46	1.48	8.10
Lymphovascular invasion	Positive	0.0418	1.72	1.02	2.90
Triple-negative	Yes	0.0179	2.36	1.16	4.81
Grade	III	0.0150	1.97	1.14	3.39

Table 4 Cox Regression, Disease-Free Survival

		P-value	HR	95% CI
Nodal metastasis	Positive	0.0012	2.64	1.46	4.76
Lymphovascular invasion	Positive	0.0349	1.54	1.03	2.29
Grade	III	0.0791	1.42	0.96	2.10

Figure 2 Disease-free survival for the nonmetastatic patients (n=354). (A) Node-positive versus node-negative; (B) grade I/II versus grade III; (C) age >30 versus ≤30 years.